Paper31014367
The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.
Ryan D and 3 others. Breast Cancer Res, 2019. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. Papers, record 31014367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31014367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alternative Splicing | Major topic |
| BRCA1 Protein | Major topic |
| Biomarkers, Tumor | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Mesenchymal Stem Cells | Major topic |
| Triple Negative Breast Neoplasms | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Dinoprostone | |
| Disease Models, Animal | |
| Female | |
| Gene Knockdown Techniques | |
| Humans | |
| Interleukin-6 | |
| Mice | |
| Models, Biological | |
| Prognosis |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA194447 | NCI NIH HHS | United States | R01CA194447 | PubMed and NIH |
Source NIH RePORTER
References75
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21376230 | Hallmarks of cancer: the next generation. | Cell | 2011 | https://conductscience.org/library/papers/21376230 | PubMed |
| 2 | 22641101 | Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. | Lab Invest | 2012 | https://conductscience.org/library/papers/22641101 | PubMed |
| 3 | 28052035 | BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. | Oncotarget | 2017 | https://conductscience.org/library/papers/28052035 | PubMed |
| 4 | 26840088 | Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/26840088 | PubMed |
| 5 | 25589616 | Interleukin-6 as a therapeutic target. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25589616 | PubMed |
| 6 | 19279573 | Microenvironmental regulation of metastasis. | Nat Rev Cancer | 2009 | https://conductscience.org/library/papers/19279573 | PubMed |
| 7 | 29844821 | Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer. | Oncol Lett | 2018 | https://conductscience.org/library/papers/29844821 | PubMed |
| 8 | 16540639 | Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. | Cancer Res | 2006 | https://conductscience.org/library/papers/16540639 | PubMed |
| 9 | 21781996 | PI3-K/Akt and ERK pathways activated by VEGF play opposite roles in MPP+-induced neuronal apoptosis. | Neurochem Int | 2011 | https://conductscience.org/library/papers/21781996 | PubMed |
| 10 | 14673173 | Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. | Mol Cell Biol | 2004 | https://conductscience.org/library/papers/14673173 | PubMed |
| 11 | 29978449 | Microenvironment in breast tumorigenesis: Friend or foe? | Histol Histopathol | 2019 | https://conductscience.org/library/papers/29978449 | PubMed |
| 12 | 25887413 | Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. | Breast Cancer Res | 2015 | https://conductscience.org/library/papers/25887413 | PubMed |
| 13 | 15448696 | Identification of BRCA1-IRIS, a BRCA1 locus product. | Nat Cell Biol | 2004 | https://conductscience.org/library/papers/15448696 | PubMed |
| 14 | 27415778 | Human Cardiac Mesenchymal Stromal Cells with CD105+CD34- Phenotype Enhance the Function of Post-Infarction Heart in Mice. | PLoS One | 2016 | https://conductscience.org/library/papers/27415778 | PubMed |
| 15 | 26714415 | Tumor Associated Mesenchymal Stromal Cells Show Higher Immunosuppressive and Angiogenic Properties Compared to Adipose Derived MSCs. | Iran J Immunol | 2015 | https://conductscience.org/library/papers/26714415 | PubMed |
| 16 | 19209259 | Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. | Ther Clin Risk Manag | 2008 | https://conductscience.org/library/papers/19209259 | PubMed |
| 17 | 27493669 | Aggressiveness Niche: Can It Be the Foster Ground for Cancer Metastasis Precursors? | Stem Cells Int | 2016 | https://conductscience.org/library/papers/27493669 | PubMed |
| 18 | 28847749 | Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer. | J Steroid Biochem Mol Biol | 2018 | https://conductscience.org/library/papers/28847749 | PubMed |
| 19 | 27272837 | Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells. | Anticancer Res | 2016 | https://conductscience.org/library/papers/27272837 | PubMed |
| 20 | 22511931 | BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. | PLoS One | 2012 | https://conductscience.org/library/papers/22511931 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41800053 | Advances in intratumoral immunotherapy from a neuro-immune-endocrine perspective for breast cancer treatment. | Front Oncol | 2026 | https://conductscience.org/library/papers/41800053 | PubMed |
| 40384197 | Contralateral breast cancer in patients carrying mutations in the BRCA1โ2 gene. | Rom J Morphol Embryol | 2025 | https://conductscience.org/library/papers/40384197 | PubMed |
| 39070181 | The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39070181 | PubMed |
| 38487526 | The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer. | Front Immunol | 2024 | https://conductscience.org/library/papers/38487526 | PubMed |
| 37781195 | Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells. | Front Oncol | 2023 | https://conductscience.org/library/papers/37781195 | PubMed |
| 37746260 | The role of breastfeeding in breast cancer prevention: a literature review. | Front Oncol | 2023 | https://conductscience.org/library/papers/37746260 | PubMed |
| 37189800 | From Interaction to Intervention: How Mesenchymal Stem Cells Affect and Target Triple-Negative Breast Cancer. | Biomedicines | 2023 | https://conductscience.org/library/papers/37189800 | PubMed |
| 36830980 | The Role of COX-2 and PGE2 in the Regulation of Immunomodulation and Other Functions of Mesenchymal Stromal Cells. | Biomedicines | 2023 | https://conductscience.org/library/papers/36830980 | PubMed |
| 35141026 | Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: the case for longer breastfeeding. | Am J Cancer Res | 2022 | https://conductscience.org/library/papers/35141026 | PubMed |
| 34670861 | Cancer-Associated Fibroblast Subpopulations With Diverse and Dynamic Roles in the Tumor Microenvironment. | Mol Cancer Res | 2022 | https://conductscience.org/library/papers/34670861 | PubMed |
| 34628623 | Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. | Hum Cell | 2022 | https://conductscience.org/library/papers/34628623 | PubMed |
| 34053447 | Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers. | BMC Cancer | 2021 | https://conductscience.org/library/papers/34053447 | PubMed |
| 33540843 | The Role of BRCA1/2-Mutated Tumor Microenvironment in Breast Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33540843 | PubMed |
| 31911557 | The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages. | Cancer Res | 2020 | https://conductscience.org/library/papers/31911557 | PubMed |
Genes36
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31014367
GET https://conductscience.org/api/papers/v1/31014367/references?page=2